Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: results from real-life setting

×

Error message

  • User warning: The following theme is missing from the file system: journalijdr. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1138 of /home2/journalijdr/public_html/includes/bootstrap.inc).
  • Deprecated function: implode(): Passing glue string after array is deprecated. Swap the parameters in drupal_get_feeds() (line 394 of /home2/journalijdr/public_html/includes/common.inc).
  • Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in _menu_load_objects() (line 579 of /home2/journalijdr/public_html/includes/menu.inc).

International Journal of Development Research

Volume: 
11
Article ID: 
23010
2 pages
Research Article

Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: results from real-life setting

Dan Călugăru and Mihai Călugăru

Received 17th August, 2021; Received in revised form 29th September, 2021; Accepted 03rd October, 2021; Published online 30th October, 2021

Copyright © 2021, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract: 

The authors are commenting on the study entitled: “Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: results from rel-life setting” published by Lukic et al. in European Journal Ophthalmology 2020 (Doi: 10.1177/1120672120938565. Published on June 25, 2020), which assessed 4-year structural and functional outcomes in intravitreal aflibercept treatment for 89 patients (94 eyes) with neovascular age-related macular degeneration in a real-world setting. The authors concluded that there was a significant improvement in visual acuity and in anatomical outcomes in aflibercept-treated eyes at 4 years after commencing treatment. However, the validation, extrapolation, and generalizabilty of these findings can only be made by statistical analyses including all the missing baseline potential risk factors referred to above by us in addition to the baseline characteristics already evaluated in this study, serving to emphasize the key metrics assessing the efficacy of intravitreal aflibercept for neovascular age-related macular degeneration.

DOI: 
https://doi.org/10.37118/ijdr.23010.10.2021
Download PDF: 
PDF icon 23010.pdf